Alamar Biosciences, Inc.ALMR

Alamar Biosciences, Inc. is trying to sell ultra-high sensitivity proteomics through a portfolio of assays, software, and subscription programmes, but the first-quarter 2026 filing reads less like a biotech blockbuster and more like a cash-strapped start-up: revenue of $26 million came with a net loss of $21.3 million, leaving shareholders with a quarterly loss of $1.74 per share and a stockholders’ equity deficit of $178.1 million. No single customer delivered 10% of revenue in the three months to 31 March 2026, and maintenance-contract revenue was immaterial, so the entire top line rests on a customer base that remains fragmented and unproven at scale.

The company’s public narrative now centres on the Technology Access Program (TAP) and the Alamar Analysis Solutions suite, which promise “industry-leading sensitivity” and “streamlined time to result,” respectively. Product pages show ARGO HT systems and NULISA multiplex assays aimed at neurology, immunology, and oncology, but the 10-Q makes plain that the cash conversion engine is still idle: net cash used in operating activities was $20.3 million in the quarter, while inventory rose to $39.9 million and capitalised R&D absorbed $13 million. The polished marketing images are striking, yet the underlying filings suggest the glamour shots are subsidising the science rather than the reverse.

Alamar’s first-quarter 2026 10-Q shows total assets of $186.5 million against liabilities of $129.5 million, leaving a cash and cash equivalents pile of $64.6 million that must cover at least two more quarters of operating losses at the current rate. Capital expenditure was a modest $600,000, while warranty accruals ticked up by $440,000, indicating that customer support is still early innings. The company’s diluted share count stood at 12.3 million shares, so every dollar of revenue is spread thinly across a widening equity base.

For context, the company’s SEC filings do not yet disclose free cash flow, segment-level margins, or formal guidance, so investors are left to infer liquidity and scaling potential from the headline cash burn and inventory build. The Technology Access Program and Alamar Analysis Solutions are live products, but their revenue contribution and customer concentration remain unquantified in the public filings; the company’s product pages and new-product rail therefore serve as colour rather than proof of traction.

You can explore the company’s product rail at Technology Access Program, Alamar Analysis Solutions, and Products and Services. The full first-quarter 2026 10-Q is available on SEC EDGAR. No analyst estimates, valuation commentary, or formal guidance are supplied in the evidence set.